Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 26, 2025Liver InternationalOpen Access

Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMonica NigerFondazione IRCCS Istituto Nazionale dei TumoriMRMargherita RiminiVita-Salute San Raffaele UniversityFCFlorian CastetHebron University

Discussion

Loading...

Member takes

Implication

Observational study demonstrates improved progression-free survival for IDH1 mutant cholangiocarcinoma with ivosidenib, indicating potential as a treatment option.

Key Points

  • Ivosidenib improves progression-free survival in IDH1 mutant cholangiocarcinoma patients, showing a median PFS of 6.9 months.
  • Patients receiving ivosidenib had an overall survival of 15.9 months compared to 9.0 months with second-line chemotherapy.
  • The study included 46 patients treated across 11 European institutions between 2021 and 2024.
  • Grade ≥3 adverse events occurred in only 8.7% of patients, suggesting a manageable safety profile.

Cite This Study

Niger et al. (2025) studied this question.

synapsesocial.com/papers/68af7c947567bf4f94ff42fehttps://doi.org/10.1111/liv.70295
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Cancer statistics, 20252025 · 3,036 citations